Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -27.16%43 EV-to-FCF is 4.71 as of Aug. 02, 2026, which is 268% above its 10-year median of 1.28. GuruFocus rates PBSV with a GF Score™ of 43/100 and a GF Value™ of $0.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 406 Healthcare Providers & Services companies, Pharma-Bio Serv ranks better than 89.41% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharma-Bio Serv's Enterprise Value is $-1.15 Mil.
Pharma-Bio Serv's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.24 Mil. Therefore, Pharma-Bio Serv's EV-to-FCF for today is 4.71.
The historical rank and industry rank for Pharma-Bio Serv's EV-to-FCF or its related term are showing as below:
PBSV'
s EV-to-FCF Range Over the Past 10 Years
Min: -56.9 Med: 1.28 Max: 99.48
Current: 4.71
During the past 13 years, the highest EV-to-FCF of Pharma-Bio Serv was 99.48. The lowest was -56.90. And the median was 1.28.
PBSV's EV-to-FCF is ranked better than 89.41% of 406
companies
in the Healthcare Providers & Services industry
Industry Median: 17.83
vs PBSV: 4.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharma-Bio Serv's PE Ratio (TTM) for today is calculated as:
Pharma-Bio Serv's share price for today is $0.4225.
Pharma-Bio Serv's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pharma-Bio Serv EV-to-FCF Related Terms
Pharma-Bio Serv EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Pharma-Bio Serv's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's EV-to-FCF falls into.
Pharma-Bio Serv's current Enterprise Value is $-1.15 Mil.
Pharma-Bio Serv's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (PBSV) has a EV-to-FCF of 4.71 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pharma-Bio Serv and its competitors. This is 268% above median its historical median of 1.28. According to the industry distribution chart, Pharma-Bio Serv ranks #43 out of 406 companies in the Healthcare Providers & Services industry, placing it in the top 10.6%.
Is Pharma-Bio Serv's EV-to-FCF too high?
Pharma-Bio Serv's current EV-to-FCF of 4.71 is 268% above median its 10-year median of 1.28. The Healthcare Providers & Services industry median EV-to-FCF is 17.83. Pharma-Bio Serv's value of 4.71 is 73.6% below this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #43 out of 406 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma-Bio Serv has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's EV-to-FCF compare to MGRX and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #43 out of 406 companies for EV-to-FCF. This places Pharma-Bio Serv in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 17.83. Pharma-Bio Serv's value of 4.71 is 73.6% below this benchmark. While the company's 10-year median is 1.28 vs. the industry median of 17.83, Pharma-Bio Serv has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.83, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current EV-to-FCF of 4.71 is 73.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current EV-to-FCF is 4.71, which is 268% above median its own 10-year median of 1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.58, compared to a current price of $0.42 — trading 27.2% below its estimated fair value. The current EV-to-FCF is 4.71, which is 268% above median its 10-year median of 1.28 and 73.6% below the Healthcare Providers & Services industry median of 17.83. Pharma-Bio Serv's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current EV-to-FCF is 4.71 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.42 is trading 27.2% below its estimated GF Value™ of $0.58.
GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.
Key valuation signals for PBSV:
EV-to-FCF: 4.71 (268% above median its 10-year median of 1.28)
GF Value™: $0.58 vs. price of $0.42 (27.2% below fair value)
Industry Position: 73.6% below the Healthcare Providers & Services median (#43 of 406)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
43GF Score
Get the complete analysis for PBSV
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
